MediPharm Labs Provides Conference Call Recording Details

Rhea-AI Summary

MediPharm Labs Corp. releases its full year and fourth quarter financial results for 2023, showing a 50% improvement in annual revenue and adjusted EBITDA. The company specializes in precision-based cannabinoids and hosted a conference call to discuss the results.

TORONTO, March 27, 2024 /PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, has released and hosted a conference call regarding its full year and fourth quarter financial results for the period ended December 31, 2023.  

MediPharm Labs executive management team thanks those were able to join the call where it discussed 2023 fourth quarter and year-end results. Highlighting that the Company annual revenue and adjusted EBITDA improved by 50%. 

For those who are unable to participate on the live conference call or webcast on March 27, 2024, a replay is now available here. 

Management Disclosure and Analysis and Financial Statements are also available on our Investor Page as well the SEDAR+ website www.sedarplus.ca

MediPharm Labs looks forward to connecting with investors again for our 2024 first quarter earnings results in May 2024.

About MediPharm Labs 

Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities for delivery of pure, trusted and precision-dosed cannabis products for its customers. MediPharm Labs develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets.

In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America to hold a commercial-scale domestic Good Manufacturing Practices License for the extraction of multiple natural cannabinoids. This GMP license was the first step in the Company's current foreign drug manufacturing site registration with the US FDA.

In 2023, MediPharm acquired VIVO Cannabis Inc. which expanded MediPharm's reach to medical patients in Canada via Canna Farms medical ecommerce platform, and in Australia and Germany through Beacon Medical PTY and Beacon Medical GMBH. This acquisition also included Harvest Medical Clinics in Canada which provides medical cannabis patients with Physician consultations for medical cannabis education and prescriptions.

The Company carries out its operations in compliance with all applicable laws in the countries in which it operates.

Cautionary Note Regarding Forward-Looking Information

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm's filings, available on the SEDAR+ website a www.sedarplus.ca. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.

View original content to download multimedia:https://www.prnewswire.com/news-releases/medipharm-labs-provides-conference-call-recording-details-302101224.html

SOURCE MediPharm Labs Corp.

FAQ

What were MediPharm Labs Corp.'s annual revenue and adjusted EBITDA improvements for 2023?

MediPharm Labs Corp. reported a 50% improvement in annual revenue and adjusted EBITDA for the year 2023.

When did MediPharm Labs Corp. release its full year and fourth quarter financial results for 2023?

MediPharm Labs Corp. released its full year and fourth quarter financial results for 2023 on March 27, 2024.

When will MediPharm Labs Corp. host its 2024 first quarter earnings results?

MediPharm Labs Corp. will host its 2024 first quarter earnings results in May 2024.